Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 39% Improvement Relative Risk Ventilation time 43% ICU time 2% Karimpour-razkenari et al. Melatonin ICU PATIENTS Is very late treatment with melatonin beneficial for COVID-19? Retrospective 31 patients in Iran (March - May 2020) Lower mortality (p=0.37) and shorter ventilation (p=0.13), not stat. sig. Karimpour-razkenari et al., Annals of Medicine a.., doi:10.1016/j.amsu.2022.103492 Favors melatonin Favors control
Melatonin as adjunctive therapy in patients admitted to the Covid-19
Karimpour-razkenari et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103492
Karimpour-razkenari et al., Melatonin as adjunctive therapy in patients admitted to the Covid-19, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103492
Mar 2022   Source   PDF  
  All Studies   Meta
Retrospective 31 ICU patients, 12 treated with melatonin, showing lower mortality with treatment, without statistical significance. Melatonin 15mg daily.
Although the 39% lower mortality is not statistically significant, it is consistent with the significant 48% lower mortality [27‑63%] from meta analysis of the 9 mortality results to date.
risk of death, 39.0% lower, HR 0.61, p = 0.37, treatment 5 of 12 (41.7%), control 13 of 19 (68.4%), NNT 3.7, Kaplan–Meier.
ventilation time, 42.9% lower, relative time 0.57, p = 0.13, treatment 12, control 19.
ICU time, 1.9% lower, relative time 0.98, p = 0.85, treatment 12, control 19.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karimpour-razkenari et al., 10 Mar 2022, retrospective, Iran, peer-reviewed, 6 authors, study period 13 March, 2020 - 30 May, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Abstract: Journal Pre-proof Melatonin as adjunctive therapy in patients admitted to the Covid-19 Elahe Karimpour-razkenari, Fahimeh Naderi-Behdani, Ali Salahshoor, Fatemeh Heydari, Abbas Alipour, Afshin Gholipour Baradari PII: S2049-0801(22)00252-7 DOI: Reference: AMSU 103492 To appear in: Annals of Medicine and Surgery Received Date: 1 February 2022 Revised Date: 3 March 2022 Accepted Date: 6 March 2022 Please cite this article as: Karimpour-razkenari E, Naderi-Behdani F, Salahshoor A, Heydari F, Alipour A, Baradari AG, Melatonin as adjunctive therapy in patients admitted to the Covid-19, Annals of Medicine and Surgery (2022), doi: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. Abstract Objective: Coronavirus has disrupted the natural order of the world since September 2019 with no specific medication. The beneficial effects of melatonin on sepsis and viral influenza were demonstrated previously, but its effects on covid-19, especially COVID -19 ICU, is unclear. Therefore, our aim was to determine the effects of melatonin in COVID-19 ICU patients. Methods: This is a retrospective cohort study in which the records of patients admitted to COVID -19 ICU of (XXX) during March to June 2020 were reviewed. According to inclusion of criteria, patients who received 15 mg of melatonin daily were called MRG and the rest were ro called NMRG. -p Results: Thirty-one patients were included and analyzed, of which twelve patients were in re MRG. Demographic and clinical characteristics, and laboratory data were similar between two lP groups at ICU admission. Melatonin had no significant effect on ICU duration, CRP and ESR, also the trend of changes was in favor of melatonin. Nevertheless, melatonin significantly na reduced the NLR (OR=-9.81, p=0.003), and also declined mortality marginally (p=0.09). Melatonin was well tolerated with no major adverse effects, moreover the thrombocytopenia ur occurrence was significantly lower in MRG (p=0.005). In MRG, survival increased and Jo mortality risk decreased, although the difference between groups wasn’t significant (p=0.37), which might be related to the small sample-size. Conclusion: Our study showed that melatonin is unlikely to reduce mortality among COVID19 patients and with no significant effect on disease-specific biochemical parameters. Keywords: melatonin, COVID -19, Mortality, thrombocytopenia
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop